Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma
Latest Information Update: 14 Oct 2021
At a glance
- Drugs Forodesine (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
- Focus Registrational; Therapeutic Use
- Sponsors BioCryst Pharmaceuticals
- 25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 28 Mar 2012 This trial is recruiting in France, United Kingdom and Spain.
- 28 Mar 2012 Additional trial locations added as reported by European Clinical Trials Database.